© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
FDA News
Your daily dose of the clinical news you may have missed.
Rezpegaldesleukin targets the IL-2 receptor complex to stimulate regulatory T cells, aiming to restore immune balance in people with atopic dermatitis.
The FDA set a PDUFA action date of December 12, 2025 for lerodalcibep, according to LIB Therapeutics.
Your daily dose of the clinical news you may have missed.
The novel therapy combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.
The FDA has set the Prescription Drug User Fee Act target action date for bronchiectasis for August 12, 2025, Insmed Incorporated announced.
Onapgo is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in people with advanced Parkinson disease.
Hardware or software changes as well as user adjustments may disable or mute alerts for elevated glycemia, medication use, and other diabetes management essentials, the agency said.
Your daily dose of the clinical news you may have missed.
The Tina-quant® Lipoprotein (a) Gen.2 Molarity assay measures Lp(a) in molar units, providing a more accurate particle-based risk assessment than mass units.